Epidermal growth factor receptor mutations in East European non-small cell lung cancer patients

Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells

(2014) Sun Hee Ahn et al.   CELLULAR ONCOLOGY

Comparison Study of the Performance of the QIAGEN EGFR RGQ and EGFR Pyro Assays for Mutation Analysis in Non–Small Cell Lung Cancer

(2013) Allison M. Cushman-Vokoun et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)

(2013) S. Dearden et al.   ANNALS OF ONCOLOGY

Lung cancer stem cells: a biological and clinical perspective

(2013) Ana Koren et al.   CELLULAR ONCOLOGY

Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer

(2013) Nir Peled et al.   CELLULAR ONCOLOGY

Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

(2012) Julian R. Molina et al.   MAYO CLINIC PROCEEDINGS

Molecular pathology of lung cancer: key to personalized medicine

(2012) Liang Cheng et al.   MODERN PATHOLOGY

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma

(2012) Alexander J. J. Smits et al.   CELLULAR ONCOLOGY

Spectrum of LKB1, EGFR, and KRAS Mutations in Chinese Lung Adenocarcinomas

(2010) Bin Gao et al.   Journal of Thoracic Oncology

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE